ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.

ADMA Biologics, Inc. specializes in developing and manufacturing plasma-derived products for patients with immune deficiencies, utilizing proprietary immunotechnology.

msh id	COM:ADMABIOLOGICS
symbol	ADMA
name	ADMA Biologics, Inc.
homepage url	https://www.admabiologics.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	624
crunchbase url	-
linkedin url	-
founders	-

market cap	2.78B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.22
growth cost of revenue	0.43
growth depreciation and amortization	65.23
growth ebitda	1.76
growth ebitda ratio	1.46
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	1.5
growth gross profit ratio	0.49

COM:ADMABIOLOGICS

ADMA Biologics, Inc.

Last Close

21.37

21/11 21:00

Market Cap

2.78B

Beta: -

Volume Today

2.00M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	236.58M
cost of revenue	236.58M
depreciation and amortization	8.33M
ebitda	29.96M
ebitda ratio	0.12
eps	-0.13
eps diluted	-0.13
operating expenses	66.59M
operating income	21.63M
operating income ratio	0.08

accounts receivables	-11.92M
capital expenditure	-4.98M
cash at beginning of period	86.52M
cash at end of period	51.35M
inventory	172.91M
working capital ttm	231.86M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-